KRAS G12D inhibitor 19, identified by its CAS number 2833695-47-7, is a small molecule designed to selectively inhibit the mutated form of the KRAS protein, specifically the G12D variant. This mutation is commonly associated with various cancers, making the development of targeted inhibitors crucial for therapeutic strategies. The compound typically exhibits characteristics such as high specificity for the KRAS G12D mutation, which helps minimize off-target effects and enhances its potential efficacy in cancer treatment. Additionally, it may possess favorable pharmacokinetic properties, including good solubility and bioavailability, which are essential for effective drug delivery. The mechanism of action generally involves binding to the mutant KRAS protein, disrupting its function and downstream signaling pathways that promote tumor growth and survival. Research into such inhibitors is ongoing, with the aim of improving outcomes for patients with KRAS-driven malignancies. As with any investigational compound, further studies are necessary to fully understand its safety profile, efficacy, and potential applications in clinical settings.

KRAS G12D inhibitor 19

2833695-47-7: KRAS G12D inhibitor 19, identified by its CAS number 2833695-47-7, is a small molecule designed to selectively inhibit the mutated form of the KRAS protein, specifically the G12D variant. This mutation is commonly associated with various cancers, making the development of targeted inhibitors crucial for therapeutic strategies. The compound typically exhibits characteristics such as high specificity for the KRAS G12D mutation, which helps minimize off-target effects and enhances its potential efficacy in cancer treatment. Additionally, it may possess favorable pharmacokinetic properties, including good solubility and bioavailability, which are essential for effective drug delivery. The mechanism of action generally involves binding to the mutant KRAS protein, disrupting its function and downstream signaling pathways that promote tumor growth and survival. Research into such inhibitors is ongoing, with the aim of improving outcomes for patients with KRAS-driven malignancies. As with any investigational compound, further studies are necessary to fully understand its safety profile, efficacy, and potential applications in clinical settings.

<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>

CAS 2833695-47-7

KRAS G12D inhibitor 19

KRAS G12D inhibitor 19

Ref: TM-T86786